The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Status: Terminated

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)

Treatments: Diagnostic Test: WB-MRI

Study type: Observational

Funder types: Other

Identifiers

NCT05208229

IRST185.08

Details and patient eligibility

About

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA

Full description

Multicentric, observational, single arm, prospective, study.

All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows:

• Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed
• At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed
• In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed.

Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST.

Enrollment: 2 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.

Exclusion criteria

• no exclusion criteria

Trial design

2 participants in 1 patient group

Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol

Description:

Patients with mCRPC enrolled in the IRST 185.03 Lu-PSMA study, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.

Treatment:

Diagnostic Test: WB-MRI